Q1

Isofol Medical AB (publ) publishes interim report, January–March 2024

By

GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. First quarter, January–March 2024 Net revenue amounted to kSEK 0 (721) and […]

Isofol Medical AB (publ) publishes interim report, January–March 2024 Read More »

Isofol Medical AB (publ) publishes interim report, January–March 2023

By

GOTHENBURG, Sweden, May 3, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2023 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. First quarter, January–March 2023 Net revenue amounted to TSEK 721 (4,006) and

Isofol Medical AB (publ) publishes interim report, January–March 2023 Read More »

Isofol Medical AB (publ) publishes interim report, January–March 2022

By

GOTHENBURG, Sweden, May 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2022 is now available on the company’s website, www.isofolmedical.com (https://isofolmedical.com/investors/financial-reports/). First quarter, January–March 2022 Net revenue amounted to TSEK 4,006 (5,215) and other revenue to TSEK 1 (0) The result for the period amounted

Isofol Medical AB (publ) publishes interim report, January–March 2022 Read More »

Scroll to Top